Medi-Weightloss Beaverton
4655 SW Griffith Dr, Suite 120 · Beaverton, OR 97005
4.8(18 Google reviews · 16 in past year)
Mia Medical Spa · 8670 Southwest Scholls Ferry Road · Beaverton, OR 97008
5.0· 126 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
The official website for Mia Medical Spa in Beaverton, OR did not load (ConnectionError: HTTPSConnectionPool(host='miamedicalspa.com', port=443): Max retries exceeded with url: / (Caused by NameResolutionError("<urllib3.connection.HTTPSConnection object at 0x7f10074d2fd0>: Failed to resolve 'miamedicalspa.com' ([Errno -3] Temporary failure in name resolution)"))), so this summary cannot be grounded in first-party page content. No medications, prices, or services are inferred from the directory dump.
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Counts computed by RetaMaps from public Google reviews; most recent review 2026-04-10. Read the reviews themselves on the practice's Google listing.
4655 SW Griffith Dr, Suite 120 · Beaverton, OR 97005
4.8(18 Google reviews · 16 in past year)
4265 Southwest 109th Avenue · Beaverton, OR 97005
4.8(82 Google reviews · 2 in past year)
14355 Southwest Allen Boulevard · Beaverton, OR 97005
5.0(86 Google reviews · 67 in past year)
12325 Southwest Horizon Boulevard · Beaverton, OR 97007
4.5(154 Google reviews · 13 in past year)
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs